TL;DR
- Retinoids are conventionally used at night — this is not arbitrary, but it is not an absolute rule for all retinoids
- Retinol is genuinely unstable in light, oxygen, and heat — this was the original practical reason for nighttime use
- Adapalene is considerably more photostable and can be used in the morning without meaningful degradation — most other retinoids, including tazarotene, remain photolabile
- The stronger reason for nighttime use is convenience and tolerability, not phototoxicity — retinoids are not considered photosensitisers in the way some medications are
- Regardless of timing, daily SPF is non-negotiable when using any retinoid — as it should be regardless
If you have ever been told to use retinoids only at night, you were told something mostly right — but more nuanced than it sounds. Night use is convention, not an absolute law.
The photostability issue
Retinol, the most common over-the-counter retinoid, is genuinely unstable. It is sensitive to light, oxygen, and heat, and exposure degrades it to less active forms, reducing efficacy over time. This was the original practical reason for the nighttime convention: apply the product in conditions where the active molecule is preserved, and store it away from light and heat between uses. Encapsulation technology has substantially improved the stability of modern retinol formulations compared to older, unprotected preparations.
Tretinoin is not as unstable as is often assumed. Older formulations had real photostability concerns, but modern microsphere and stabilised tretinoin preparations are considerably improved. Nighttime use remains standard practice for tretinoin, but this reflects convention and tolerability considerations as much as a strict chemical requirement.
Not all retinoids share retinol’s instability. Adapalene, available over the counter in many countries, is considerably more photostable than tretinoin or retinol — UV does not meaningfully degrade it, and it can be used in the morning without significant loss of efficacy. Tazarotene, by contrast, remains photolabile and does not share this photostability advantage. The nighttime convention for adapalene specifically is largely historical and practical rather than chemically necessary.
The stronger argument for nighttime use
The more defensible reason to use retinoids at night is not phototoxicity but tolerability. Contrary to older explanations, current evidence does not strongly support the older explanation that retinoids produce clinically important UV vulnerability through progressive thinning of the skin — in fact, studies have found that long-term tretinoin use does not reduce epidermal thickness below baseline, and the concern about stratum corneum thinning with sustained use appears overstated. Retinoids are not considered photosensitisers in the way that certain medications, such as doxycycline, are.
The practical issue is irritation, not phototoxicity. Retinoids commonly cause dryness, peeling, and sensitivity during the adjustment period, and irritated skin generally tolerates sun exposure less comfortably. Applying the retinoid in the evening and following with consistent daytime photoprotection is the sensible sequence — not because morning application is chemically dangerous, but because managing retinoid-induced irritation alongside daytime sun exposure is simply easier to do well when the irritation phase happens overnight.
The practical rule
Use retinoids at night by default. This is the most conservative approach, suits most people, and aligns with photostability concerns for retinol and tretinoin specifically. If you use adapalene and prefer a morning application for routine reasons, it is not chemically problematic — daily SPF remains important, as it always should be, rather than requiring some heightened standard of sun protection beyond normal good practice.
The single non-negotiable: SPF every morning, every day, when using any retinoid — the same standard that applies to everyone regardless of retinoid use. The convention of nighttime retinoid application is the delivery mechanism for that rule, not a separate rule in itself.
⚠️ Clinical note: The older explanation that retinoids increase UV vulnerability through stratum corneum thinning is increasingly viewed as incomplete by contemporary dermatology. The evidence for retinoids causing genuine phototoxicity is mixed, and adapalene in particular may not increase UV sensitivity at all. The practical case for nighttime use rests primarily on tolerability and historical photostability concerns with specific formulations, not a universal phototoxic effect.
Sources
- Gulliver WP. Adapalene. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available at: ncbi.nlm.nih.gov/books/NBK482509/ [“This stability contrasts with both tretinoin and tazarotene, which are photolabile.”]
- Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(Suppl 52):8–11. doi:10.1046/j.1365-2133.1998.1390s2008.x
- Nyirady J, Lucas C, Yusuf M, Mignone P, Wisniewski S. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis. 2002;70(5):295–298.
- Bhawan J, Gonzalez-Serva A, Nehal K, et al. Effects of tretinoin on photodamaged skin: a histologic study. Arch Dermatol. 1991;127(5):666–672. [Epidermal thickening early; returns toward baseline at 12–24 months; no below-baseline thinning on long-term use.]
- Griffiths CEM, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. Arch Dermatol. 1995;131(9):1037–1044.
- Stanfield J, et al. Reappraising the phototoxicity of tretinoin: a report of four controlled clinical trials. Photodermatol Photoimmunol Photomed. 2009. [Tretinoin did not cause phototoxicity or photoallergy in controlled testing.]
- Ferguson J, Johnson BE. Photosensitivity due to retinoids: clinical and laboratory studies. Br J Dermatol. 1986;115(3):275–283. doi:10.1111/j.1365-2133.1986.tb05742.x
